Sickle Cell Disease Clinical Trials in Washington D.C., District of Columbia

11 studies are recruiting for sickle cell disease in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

2. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Childrens National Medical Ctr, Washington D.C., District of Columbia

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

3. A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

   A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

   Stage

   Phase 3

   Ages

   12 to 100

   Site

   Childrens National Hospital, Washington D.C., District of Columbia

   Locations

   35 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06439082 on ClinicalTrials.gov

4. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Georgetown University, Washington D.C., District of Columbia

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

5. Cooperative Assessment of Late Effects for SCD Curative Therapies

   Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with >…

   Stage

   Not phased

   Ages

   4 to 65

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   5 in total

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT05153967 on ClinicalTrials.gov

6. Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

   This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

   Stage

   Phase 4

   Ages

   0 to 100

   Site

   Childrens National Hospital, Washington D.C., District of Columbia

   Locations

   31 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04657822 on ClinicalTrials.gov

7. Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

   The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are: * Does intravenous citrulline decrease the dura…

   Stage

   Phase 2

   Ages

   4 to 21

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Run by

   Suvankar Majumdar

   See if you can join NCT06635902 on ClinicalTrials.gov

8. Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

   This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate …

   Stage

   Phase 2

   Ages

   2 to 25

   Site

   Children's National Health System, Washington D.C., District of Columbia

   Locations

   7 in total

   Run by

   Robert Nickel

   See if you can join NCT03587272 on ClinicalTrials.gov

9. Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

   This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor r…

   Stage

   Phase 2

   Ages

   2 to 25

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Run by

   Children's National Research Institute

   See if you can join NCT06358638 on ClinicalTrials.gov

10. Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

    This is a single site nonrandomized pilot clinical trial of the feasibility, acceptability, and efficacy of a combination treatment involving digital Cogmed working memory skills training, social support components, and memory strategy training to improve adherence to Cogmed in youth with sickle ce…

    Stage

    Not phased

    Ages

    7 to 16

    Site

    Children's National Hospital, Washington D.C., District of Columbia

    Run by

    Children's National Research Institute

    See if you can join NCT06770010 on ClinicalTrials.gov

11. Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

    Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program …

    Stage

    Not phased

    Ages

    8 to 16

    Site

    Children's National Hospital, Washington D.C., District of Columbia

    Run by

    Children's National Research Institute

    See if you can join NCT05099874 on ClinicalTrials.gov